NASDAQ:OCUL - Ocular Therapeutix Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $24.80
  • Forecasted Upside: 115.65 %
  • Number of Analysts: 4
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 2 Buy Ratings
  • 1 Strong Buy Ratings
▲ +0.17 (1.50%)

This chart shows the closing price for OCUL by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Ocular Therapeutix Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for OCUL and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for OCUL

Analyst Price Target is $24.80
▲ +115.65% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Ocular Therapeutix in the last 3 months. The average price target is $24.80, with a high forecast of $30.00 and a low forecast of $14.00. The average price target represents a 115.65% upside from the last price of $11.50.

This chart shows the closing price for OCUL for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 4 investment analysts is to buy stock in Ocular Therapeutix. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart

  • 1 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 0 sell ratings
  • 1 strong buy ratings
  • 4 buy ratings
  • 2 hold ratings
  • 0 sell ratings
  • 1 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
  • 1 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
  • 1 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
  • 1 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
  • 1 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
  • 1 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Latest Recommendations

  • 1 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
7/23/2021Piper SandlerReiterated RatingBuy$28.00High
12/30/2020JMP SecuritiesBoost Price Target$20.00 ➝ $30.00N/A
12/28/2020HC WainwrightDowngradeBuy ➝ NeutralN/A
12/21/2020Piper SandlerBoost Price Target$16.00 ➝ $28.00Low
12/17/2020Berenberg BankInitiated CoverageBuy$27.00Medium
11/13/2020Raymond JamesBoost Price TargetStrong-Buy$15.00 ➝ $25.00High
11/6/2020HC WainwrightBoost Price TargetBuy$13.00 ➝ $14.00High
9/30/2020HC WainwrightReiterated RatingBuy$13.00High
8/10/2020HC WainwrightBoost Price TargetBuy$10.00 ➝ $13.00High
7/22/2020Piper SandlerBoost Price TargetOverweight$11.00 ➝ $14.00Low
4/29/2020HC WainwrightReiterated RatingPositive ➝ Buy$8.00 ➝ $10.00High
3/17/2020Jefferies Financial GroupInitiated CoverageBuy$8.00High
3/5/2020Piper SandlerReiterated RatingOverweight$7.00 ➝ $11.00High
3/4/2020HC WainwrightReiterated RatingBuy$8.00High
3/3/2020Raymond JamesUpgradeOutperform ➝ Strong-BuyHigh
2/10/2020Piper SandlerBoost Price Target$5.50 ➝ $7.00Low
2/10/2020HC WainwrightReiterated RatingBuy ➝ Positive$6.00 ➝ $8.00Medium
11/15/2019HC WainwrightReiterated RatingBuy$9.00 ➝ $6.00High
11/12/2019Piper Jaffray CompaniesLower Price TargetOverweight$8.00 ➝ $5.00High
10/18/2019HC WainwrightReiterated RatingBuy$9.00Low
9/25/2019HC WainwrightReiterated RatingBuy$9.00High
7/26/2019Piper Jaffray CompaniesSet Price TargetBuy$8.00N/A
7/2/2019Piper Jaffray CompaniesSet Price TargetBuy$8.00Low
7/2/2019HC WainwrightSet Price TargetBuy$9.00Low
6/24/2019HC WainwrightReiterated RatingBuy$9.00High
6/21/2019JMP SecuritiesSet Price TargetBuy$9.00Low
5/21/2019HC WainwrightLower Price TargetBuy$12.00 ➝ $9.00High
5/21/2019Raymond JamesDowngradeStrong-Buy ➝ Outperform$11.00 ➝ $5.00High
5/21/2019CowenDowngradeOutperform ➝ Market Perform$13.00 ➝ $3.00High
5/20/2019Piper Jaffray CompaniesLower Price TargetOverweight ➝ Market Perform$8.00High
3/8/2019Piper Jaffray CompaniesSet Price TargetBuy$14.00Medium
3/7/2019Cantor FitzgeraldReiterated RatingBuy$24.00Low
1/11/2019HC WainwrightSet Price TargetBuy$12.00Low
12/4/2018HC WainwrightReiterated RatingBuy$12.00Medium
12/4/2018CowenReiterated RatingBuy$13.00Medium
12/3/2018Cantor FitzgeraldBoost Price TargetOverweight ➝ Overweight$22.00 ➝ $24.00High
11/14/2018Raymond JamesInitiated CoverageStrong-Buy ➝ Strong-Buy$10.00High
10/11/2018JMP SecuritiesReiterated RatingBuy$9.00High
10/10/2018HC WainwrightSet Price TargetBuy$10.00Medium
10/3/2018Cantor FitzgeraldSet Price TargetBuy$22.00Low
9/6/2018Piper Jaffray CompaniesInitiated CoverageOverweight ➝ OverweightLow
8/20/2018JMP SecuritiesSet Price TargetBuy$9.00Low
8/8/2018HC WainwrightSet Price TargetBuy$10.00High
8/7/2018Cantor FitzgeraldSet Price TargetBuy$22.00High
7/20/2018HC WainwrightSet Price TargetBuy$10.00High
7/19/2018Cantor FitzgeraldSet Price TargetBuy$22.00High
7/2/2018HC WainwrightSet Price TargetBuy$10.00Low
6/21/2018HC WainwrightReiterated RatingBuy$10.00High
5/9/2018HC WainwrightSet Price TargetBuy$10.00High
5/8/2018Cantor FitzgeraldSet Price TargetBuy$22.00High
3/11/2018BTIG ResearchReiterated RatingBuyHigh
3/9/2018HC WainwrightReiterated RatingBuy$10.00Low
3/8/2018Cantor FitzgeraldReiterated RatingBuy$22.00Low
1/19/2018BTIG ResearchUpgradeNeutral ➝ BuyHigh
11/8/2017HC WainwrightReiterated RatingBuy$10.00N/A
10/23/2017GuggenheimInitiated CoverageBuy$12.00N/A
9/25/2017Cantor FitzgeraldReiterated RatingBuy$21.00Low
8/10/2017BTIG ResearchReiterated RatingNeutralLow
8/9/2017HC WainwrightReiterated RatingBuy$10.00High
8/2/2017HC WainwrightSet Price TargetBuy$10.00High
7/26/2017HC WainwrightInitiated CoverageBuy ➝ Buy$10.00Low
7/17/2017BTIG ResearchReiterated RatingNeutralLow
7/14/2017Morgan StanleyReiterated RatingEqual Weight$16.00 ➝ $8.00Low
7/12/2017Cantor FitzgeraldLower Price TargetOverweight ➝ Overweight$35.00 ➝ $21.00High
7/10/2017Cantor FitzgeraldSet Price TargetBuy$35.00Medium
6/23/2017Morgan StanleyDowngradeOverweight ➝ Equal Weight$16.00High
5/15/2017Cantor FitzgeraldReiterated RatingOverweight$35.00Low
5/15/2017BTIG ResearchDowngradeBuy ➝ NeutralLow
5/5/2017Cantor FitzgeraldReiterated RatingOverweight$35.00Low
5/5/2017BTIG ResearchDowngradeBuy ➝ NeutralMedium
3/21/2017Cantor FitzgeraldReiterated RatingOverweightLow
3/21/2017BTIG ResearchReiterated RatingBuy$13.00Low
3/13/2017CowenReiterated RatingOutperform$60.00Medium
3/11/2017Cantor FitzgeraldSet Price TargetBuy$35.00Medium
2/9/2017Cantor FitzgeraldInitiated CoverageOverweight$35.00N/A
1/24/2017BTIG ResearchReiterated RatingBuy$13.00N/A
11/15/2016Royal Bank of CanadaReiterated RatingOutperform$30.00 ➝ $32.00N/A
11/15/2016Royal Bank of CanadaBoost Price TargetOutperform$30.00 ➝ $32.00N/A
10/23/2016BTIG ResearchReiterated RatingBuy$18.00N/A
10/15/2016BTIG ResearchReiterated RatingBuy$18.00N/A
8/11/2016JMP SecuritiesInitiated CoverageOutperform$21.00 ➝ $5.84N/A
(Data available from 7/28/2016 forward)
Ocular Therapeutix logo
Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel platform technology. The company markets ReSure Sealant, an ophthalmic device designed to prevent wound leaks in corneal incisions following cataract surgery; and DEXTENZA, a dexamethasone ophthalmic insert to treat ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is also developing OTX-TKI, an axitinib intravitreal implant administered by the fine-gauge needle that is in phase 1 clinical trial for the treatment of wet age-related macular degeneration; OTX-TIC, a travoprost intracameral implant, which is in phase 1 clinical trial for the reduction of intraocular pressure in patients with glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that is in phase 2 clinical trial for the chronic treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trial for the short-term treatment of the signs and symptoms of dry eye disease. In addition, the company is involved in the development of OTX-AFS, an aflibercept suprachoroidal injection for the treatment of retinal diseases. It has a strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the Company's sustained-release hydrogel in combination with Regeneron's large molecule VEGF-targeting compounds for the treatment of retinal diseases; and AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.
Read More

Today's Range

Now: $11.50
Low: $11.42
High: $11.53

50 Day Range

MA: $13.66
Low: $11.27
High: $15.04

52 Week Range

Now: $11.50
Low: $7.14
High: $24.30


1,066 shs

Average Volume

993,047 shs

Market Capitalization

$877.36 million

P/E Ratio


Dividend Yield




Frequently Asked Questions

What sell-side analysts currently cover shares of Ocular Therapeutix?

The following Wall Street sell-side analysts have issued stock ratings on Ocular Therapeutix in the last year: Berenberg Bank, HC Wainwright, JMP Securities, Piper Sandler, Raymond James, and Zacks Investment Research.
View the latest analyst ratings for OCUL.

What is the current price target for Ocular Therapeutix?

5 Wall Street analysts have set twelve-month price targets for Ocular Therapeutix in the last year. Their average twelve-month price target is $24.80, suggesting a possible upside of 115.7%. JMP Securities has the highest price target set, predicting OCUL will reach $30.00 in the next twelve months. HC Wainwright has the lowest price target set, forecasting a price of $14.00 for Ocular Therapeutix in the next year.
View the latest price targets for OCUL.

What is the current consensus analyst rating for Ocular Therapeutix?

Ocular Therapeutix currently has 1 hold rating, 2 buy ratings and 1 strong buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe OCUL will outperform the market and that investors should add to their positions of Ocular Therapeutix.
View the latest ratings for OCUL.

What other companies compete with Ocular Therapeutix?

How do I contact Ocular Therapeutix's investor relations team?

Ocular Therapeutix's physical mailing address is 15 CROSBY DRIVE, BEDFORD MA, 01730. The biopharmaceutical company's listed phone number is (781) 357-4000 and its investor relations email address is [email protected] The official website for Ocular Therapeutix is